Developer docs
API playgroundTry for free, no card

Search company profiles

Codagenix

Full company profile

uuid0000q7z

Namestring
Codagenix
Legal namestring
Codagenix, Inc.
Websiteurl
codagenix.com
Company typeenum
Private
Founded yearint
2015
Short descriptiontext

Codagenix is a clinical-stage biotechnology company developing live-attenuated viral vaccines and cancer virotherapeutics using proprietary codon deoptimization technology, serving global health, oncology, and animal health markets via partnerships with WHO, PATH, Serum Institute of India, and the US Department of Defense.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFarmingdale, United States
HQ citystring
Farmingdale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
live-attenuated vaccines, codon deoptimization, synthetic biology platform, viral vaccine development, cancer virotherapy
Industry5 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAKAM
Vaccine R&D, Clinical/Field Trials & Regulatory Affairs
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Vaccines
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Government Research Contracts and Grants
TypeLicensing Royalties
Description

Funding from US Department of Defense for dengue vaccine development ($4.4M and $5.88M awards), supporting Phase 1 trials and clinical development.

codagenix.com
2Series B Extension Funding
TypeLicensing Royalties
Description

Venture capital funding round led by Serum Institute of India with participation from Euclidean Capital and Adjuvant Capital for clinical development of vaccines and oncology programs.

vcnewsdaily.com
3Strategic Partnerships and Licensing
TypeLicensing Royalties
Description

Collaborations with WHO, PATH, Serum Institute of India, and Gates Foundation for vaccine development, manufacturing, and global delivery.

vcaonline.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1CodaVax
Description

Live-attenuated vaccine platform for RSV and influenza

codagenix.com
+4 more records
Core offering1 text field

Codagenix develops live-attenuated viral vaccines and cancer virotherapeutics using its proprietary codon deoptimization platform, which uses synthetic biology and machine learning to design hundreds of precise genetic edits into viral genomes. The company sells investigational vaccine candidates and virotherapeutic products for infectious diseases, oncology, and animal health to government agencies, global health organizations, and via co-development partnerships with manufacturers such as Serum Institute of India.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 80% reduction in new type 2 circulating vaccine-derived poliovirus emergences with nOPV2 compared to traditional Sabin OPV2
+2 more records
Product overview1 text field

Codagenix is a clinical-stage biotechnology company that has developed a proprietary synthetic biology-driven platform combining live-attenuated virus design with codon deoptimization technology. The company's product portfolio spans three core areas: (1) Infectious Disease Vaccines including CDX-DENV (dengue), CodaVax-RSV, CodaVax-H1N1 (influenza/pandemic), CoviLiv (COVID-19), Polio nOPV vaccine candidates, Yellow Fever, and CDX-ZiKV (Zika); (2) Cancer Virotherapeutics including CodaLytic for breast cancer and CDX-Onc for solid tumors; and (3) Animal Health Vaccines for farm animals (swine, poultry, cattle) and companion animals (canine). The platform enables rapid design and development of vaccine candidates, going from genetic sequence to viable candidate in weeks, with hundreds of intentionally placed genetic edits ensuring genetic stability.

Product and service11 records
1CDX-DENV (Dengue Vaccine)
CategoryInfectious Disease Vaccine
Description

A tetravalent dengue vaccine candidate leveraging codon deoptimization to design fully-homologous, contemporary strains that demonstrate balanced safety and immunogenicity across all four dengue virus serotypes in primates. Targeted at the approximately 2.5 billion people living in dengue-endemic regions globally.

2CodaVax-RSV
CategoryInfectious Disease Vaccine
Description

An intranasal respiratory syncytial virus (RSV) vaccine candidate that is genetically stable, induces meaningful T cell responses, and has demonstrated efficacy against wild-type challenge in primates. Phase 1 trials have been completed in healthy adults with ongoing trials in toddlers and infants.

3CodaVax-H1N1
CategoryInfectious Disease Vaccine
Description

A pandemic influenza vaccine candidate designed as an intranasal, pan-type A live-attenuated virus vaccine demonstrating cross-protection in animal models, including against highly pathogenic H5N1 strains.

4CoviLiv
CategoryInfectious Disease Vaccine
Description

A live-attenuated intranasal COVID-19 vaccine candidate that safely enables a broad antibody and T-cell immune response, developed in partnership with the World Health Organization and Serum Institute of India for global delivery to places in need.

5Polio (nOPV) Vaccine Candidates
CategoryInfectious Disease Vaccine
Description

Novel oral poliovirus vaccine candidates (nOPV) modified using proprietary synthetic biology technology to reduce recombination risk with other enteroviruses, enhancing genetic stability compared to traditional Sabin oral polio vaccines. The nOPV2 platform has been deployed in over 1.8 billion doses globally during outbreak response with an estimated 80% reduction in emergence of new type 2 variant polio strains.

6Yellow Fever Vaccine
CategoryInfectious Disease Vaccine
Description

A synthesized vaccine strain targeting yellow fever, a mosquito-borne viral disease with expanding geographic threat, designed for clinical development using an FDA-accepted surrogate endpoint for accelerated approval.

7CDX-ZiKV (Zika Vaccine)
CategoryInfectious Disease Vaccine
Description

A Zika virus vaccine candidate redesigned using Codagenix's platform to produce a product that is safe and immunogenic in primates, addressing the mosquito-borne virus associated with microencephaly in infants.

8CodaLytic
CategoryOncology Virotherapeutic
Description

An influenza-based virotherapeutic candidate and Codagenix's lead oncology product for breast cancer, designed to modulate the tumor microenvironment through multiple mechanisms, triggering anti-tumor immune responses in preclinical models.

9CDX-Onc (Solid Tumors)
CategoryOncology Virotherapeutic
Description

A virotherapeutic platform targeting solid tumors, leveraging the codon deoptimization platform to construct target-specific immunotherapies focusing on immunologically cold tumors, broadening and deepening patient populations benefiting from established immunotherapies.

10Farm Animal Vaccines
CategoryAnimal Health Vaccine
Description

Vaccines for agricultural animals including swine, poultry, and cattle, targeting viral and bacterial infections to reduce agricultural losses and empower the agricultural community to reduce antibiotic use in production animals.

11Companion Animal Vaccines
CategoryAnimal Health Vaccine
Description

Vaccines for companion animals including canine, providing better protection against common and emerging diseases to increase healthy life years and improve quality of life for pets and owners.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1PATH
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-22
Description

Collaboration agreement funded by Gates Foundation to apply proprietary synthetic biology technology to fortify novel oral poliovirus vaccine (nOPV) strains against recombination with other enteroviruses, reducing risk of emergence of potentially neurovirulent vaccine-derived polioviruses. Codagenix will develop nOPV-maxSD strains with intent to establish in vitro proof of concept.

codagenix.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with WHO to develop, manufacture and deliver CoviLiv, a novel intranasal COVID-19 vaccine candidate, to places in need around the world.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Serum Institute of India to manufacture and deliver CoviLiv COVID-19 vaccine candidate globally. Serum Institute also led the $25M Series B extension funding round.

Strategic tierFoundationalTypeTechnology or Integration
Description

Technology origin: Codagenix was founded based on technology developed in the laboratory of National Academy of Science member Dr. Eckard Wimmer at Stony Brook University.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large mRNA platform company with approved COVID-19 vaccine and clinical-stage RSV, influenza, and pandemic preparedness programs — competes with Codagenix's infectious disease pipeline and has substantially greater resources.

TypeDirect peer
Description

Clinical-stage developer of live virus vaccines (e.g., horsepox-based COVID-19 vaccine platform) that, like Codagenix, uses attenuated viral platforms for infectious disease prevention.

TypeBroad incumbent
Description

Large global vaccine manufacturer (rotavirus, polio, typhoid) with strong ties to global health organizations, comparable to Codagenix's strategic partner ecosystem including Serum Institute of India.

TypeDirect peer
Description

Clinical-stage viral vector vaccine developer (MERS, HPV, hepatitis B) that, like Codagenix, targets infectious disease with a platform-based approach and pursues global health partnerships.

TypeDirect peer
Description

Clinical-stage developer of oral vaccines (including RSV and COVID-19 candidates) using a non-replicating viral vector platform — competes with Codagenix's intranasal live-attenuated programs in the same indications.

TypeDirect peer
Description

mRNA vaccine developer competing with Codagenix in influenza, COVID-19, and RSV, representing the alternative vaccine modality (mRNA) that Codagenix positions its live-attenuated platform against.

TypeDirect peer
Description

Clinical-stage biotech developing live-attenuated vaccines for RSV and other respiratory viruses, sharing Codagenix's live-attenuated vaccine approach and intranasal delivery focus.

TypeEmerging player
Description

Early-stage virotherapeutics company developing codon-modified viral immunotherapies for cancer and infectious disease — directly comparable to Codagenix's synthetic virology platform, though focused on different therapeutic areas.

TypeEmerging player
Description

Clinical-stage oncolytic virus developer building engineered virotherapeutics for solid tumors — competes with Codagenix's CodaLytic and CDX-Onc oncology programs in the same immunotherapy space.

TypeDirect peer
Description

Clinical-to-commercial stage vaccine developer with recombinant nanoparticle COVID-19 and influenza vaccines, competing for the same global health and pandemic preparedness markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Codagenix

Codagenix is a clinical-stage biotechnology company developing live-attenuated viral vaccines and cancer virotherapeutics using proprietary codon deoptimization technology, serving global health, oncology, and animal health markets via partnerships with WHO, PATH, Serum Institute of India, and the US Department of Defense.

Codagenix firmographics

Firmographics
Name
Codagenix
Legal name
Codagenix, Inc.
Website
https://codagenix.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Codagenix is a clinical-stage biotechnology company developing live-attenuated viral vaccines and cancer virotherapeutics using proprietary codon deoptimization technology, serving global health, oncology, and animal health markets via partnerships with WHO, PATH, Serum Institute of India, and the US Department of Defense.
Ownership category
akta.pro rank

Codagenix industry classification

Industry
Product category
Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAKAM
Vaccine R&D, Clinical/Field Trials & Regulatory Affairs

Keywords

  • Live-attenuated vaccines
  • Codon deoptimization
  • Synthetic biology platform
  • Viral vaccine development
  • Cancer virotherapy

Where Codagenix is headquartered

Location

Headquarters

HQ city
Farmingdale
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Codagenix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Government Research Contracts and Grants: Funding from US Department of Defense for dengue vaccine development ($4.4M and $5.88M awards), supporting Phase 1 trials and clinical development.
  2. Series B Extension Funding: Venture capital funding round led by Serum Institute of India with participation from Euclidean Capital and Adjuvant Capital for clinical development of vaccines and oncology programs.
  3. Strategic Partnerships and Licensing: Collaborations with WHO, PATH, Serum Institute of India, and Gates Foundation for vaccine development, manufacturing, and global delivery.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Codagenix product offering

Product offering

Core offering

Codagenix develops live-attenuated viral vaccines and cancer virotherapeutics using its proprietary codon deoptimization platform, which uses synthetic biology and machine learning to design hundreds of precise genetic edits into viral genomes. The company sells investigational vaccine candidates and virotherapeutic products for infectious diseases, oncology, and animal health to government agencies, global health organizations, and via co-development partnerships with manufacturers such as Serum Institute of India.

Product overview

Codagenix is a clinical-stage biotechnology company that has developed a proprietary synthetic biology-driven platform combining live-attenuated virus design with codon deoptimization technology. The company's product portfolio spans three core areas: (1) Infectious Disease Vaccines including CDX-DENV (dengue), CodaVax-RSV, CodaVax-H1N1 (influenza/pandemic), CoviLiv (COVID-19), Polio nOPV vaccine candidates, Yellow Fever, and CDX-ZiKV (Zika); (2) Cancer Virotherapeutics including CodaLytic for breast cancer and CDX-Onc for solid tumors; and (3) Animal Health Vaccines for farm animals (swine, poultry, cattle) and companion animals (canine). The platform enables rapid design and development of vaccine candidates, going from genetic sequence to viable candidate in weeks, with hundreds of intentionally placed genetic edits ensuring genetic stability.

Differentiator

Problem solved

Functional benefit

Brands

  • CodaVax: Live-attenuated vaccine platform for RSV and influenza
  • CoviLiv
  • CodaLytic
  • CDX-DENV
  • CDX-ZiKV

Products and services

  • CDX-DENV (Dengue Vaccine) A tetravalent dengue vaccine candidate leveraging codon deoptimization to design fully-homologous, contemporary strains that demonstrate balanced safety and immunogenicity across all four dengue virus serotypes in primates. Targeted at the approximately 2.5 billion people living in dengue-endemic regions globally.
  • CodaVax-RSV An intranasal respiratory syncytial virus (RSV) vaccine candidate that is genetically stable, induces meaningful T cell responses, and has demonstrated efficacy against wild-type challenge in primates. Phase 1 trials have been completed in healthy adults with ongoing trials in toddlers and infants.
  • CodaVax-H1N1 A pandemic influenza vaccine candidate designed as an intranasal, pan-type A live-attenuated virus vaccine demonstrating cross-protection in animal models, including against highly pathogenic H5N1 strains.
  • CoviLiv A live-attenuated intranasal COVID-19 vaccine candidate that safely enables a broad antibody and T-cell immune response, developed in partnership with the World Health Organization and Serum Institute of India for global delivery to places in need.
  • Polio (nOPV) Vaccine Candidates Novel oral poliovirus vaccine candidates (nOPV) modified using proprietary synthetic biology technology to reduce recombination risk with other enteroviruses, enhancing genetic stability compared to traditional Sabin oral polio vaccines. The nOPV2 platform has been deployed in over 1.8 billion doses globally during outbreak response with an estimated 80% reduction in emergence of new type 2 variant polio strains.
  • Yellow Fever Vaccine A synthesized vaccine strain targeting yellow fever, a mosquito-borne viral disease with expanding geographic threat, designed for clinical development using an FDA-accepted surrogate endpoint for accelerated approval.
  • CDX-ZiKV (Zika Vaccine) A Zika virus vaccine candidate redesigned using Codagenix's platform to produce a product that is safe and immunogenic in primates, addressing the mosquito-borne virus associated with microencephaly in infants.
  • CodaLytic An influenza-based virotherapeutic candidate and Codagenix's lead oncology product for breast cancer, designed to modulate the tumor microenvironment through multiple mechanisms, triggering anti-tumor immune responses in preclinical models.
  • CDX-Onc (Solid Tumors) A virotherapeutic platform targeting solid tumors, leveraging the codon deoptimization platform to construct target-specific immunotherapies focusing on immunologically cold tumors, broadening and deepening patient populations benefiting from established immunotherapies.
  • Farm Animal Vaccines Vaccines for agricultural animals including swine, poultry, and cattle, targeting viral and bacterial infections to reduce agricultural losses and empower the agricultural community to reduce antibiotic use in production animals.
  • Companion Animal Vaccines Vaccines for companion animals including canine, providing better protection against common and emerging diseases to increase healthy life years and improve quality of life for pets and owners.

Quantifiable outcome

  • 80% reduction in new type 2 circulating vaccine-derived poliovirus emergences with nOPV2 compared to traditional Sabin OPV2
  • +2 more outcomes

Companies that use Codagenix

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles5 records

Codagenix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Codagenix partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and foundational.

  • PATHcoreStrategic or Co-development Partner · 22 July 2025Collaboration agreement funded by Gates Foundation to apply proprietary synthetic biology technology to fortify novel oral poliovirus vaccine (nOPV) strains against recombination with other enteroviruses, reducing risk of emergence of potentially neurovirulent vaccine-derived polioviruses. Codagenix will develop nOPV-maxSD strains with intent to establish in vitro proof of concept.
  • World Health OrganizationcoreStrategic or Co-development PartnerPartnership with WHO to develop, manufacture and deliver CoviLiv, a novel intranasal COVID-19 vaccine candidate, to places in need around the world.
  • Serum Institute of IndiacoreStrategic or Co-development PartnerPartnership with Serum Institute of India to manufacture and deliver CoviLiv COVID-19 vaccine candidate globally. Serum Institute also led the $25M Series B extension funding round.
  • Stony Brook UniversityfoundationalTechnology or IntegrationTechnology origin: Codagenix was founded based on technology developed in the laboratory of National Academy of Science member Dr. Eckard Wimmer at Stony Brook University.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Codagenix competitors and assessment

Company assessment

Broad incumbents

  • Moderna: Large mRNA platform company with approved COVID-19 vaccine and clinical-stage RSV, influenza, and pandemic preparedness programs — competes with Codagenix's infectious disease pipeline and has substantially greater resources.
  • Bharat Biotech: Large global vaccine manufacturer (rotavirus, polio, typhoid) with strong ties to global health organizations, comparable to Codagenix's strategic partner ecosystem including Serum Institute of India.

Direct peers

  • Tonix Pharmaceuticals: Clinical-stage developer of live virus vaccines (e.g., horsepox-based COVID-19 vaccine platform) that, like Codagenix, uses attenuated viral platforms for infectious disease prevention.
  • Vaccitech: Clinical-stage viral vector vaccine developer (MERS, HPV, hepatitis B) that, like Codagenix, targets infectious disease with a platform-based approach and pursues global health partnerships.
  • Vaxart: Clinical-stage developer of oral vaccines (including RSV and COVID-19 candidates) using a non-replicating viral vector platform — competes with Codagenix's intranasal live-attenuated programs in the same indications.
  • CureVac: mRNA vaccine developer competing with Codagenix in influenza, COVID-19, and RSV, representing the alternative vaccine modality (mRNA) that Codagenix positions its live-attenuated platform against.
  • Meissa Vaccines: Clinical-stage biotech developing live-attenuated vaccines for RSV and other respiratory viruses, sharing Codagenix's live-attenuated vaccine approach and intranasal delivery focus.
  • Novavax: Clinical-to-commercial stage vaccine developer with recombinant nanoparticle COVID-19 and influenza vaccines, competing for the same global health and pandemic preparedness markets.

Emerging players

  • CaroGen Corporation: Early-stage virotherapeutics company developing codon-modified viral immunotherapies for cancer and infectious disease — directly comparable to Codagenix's synthetic virology platform, though focused on different therapeutic areas.
  • Vyriad: Clinical-stage oncolytic virus developer building engineered virotherapeutics for solid tumors — competes with Codagenix's CodaLytic and CDX-Onc oncology programs in the same immunotherapy space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Codagenix social profiles

Digital presence

Codagenix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Codagenix leadership team

Management profile

Number of profiles

Profiles9 records

Codagenix funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Codagenix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Codagenix

What does Codagenix do?

Codagenix develops live-attenuated viral vaccines and cancer virotherapeutics using its proprietary codon deoptimization platform, which uses synthetic biology and machine learning to design hundreds of precise genetic edits into viral genomes. The company sells investigational vaccine candidates and virotherapeutic products for infectious diseases, oncology, and animal health to government agencies, global health organizations, and via co-development partnerships with manufacturers such as Serum Institute of India.

Is Codagenix a public or private company?

Codagenix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Codagenix founded?

Codagenix was founded in 2015. It employs 11 to 50 people.

Where is Codagenix based?

Codagenix is headquartered in Farmingdale, United States, in the North America region.

How does Codagenix make money?

Three revenue lines are on record. Government Research Contracts and Grants are the primary driver. The others are series B Extension Funding and strategic Partnerships and Licensing.

Who are Codagenix's main competitors?

Broad incumbents on record are Moderna and Bharat Biotech. Direct peers are Tonix Pharmaceuticals, Vaccitech, Vaxart, CureVac, Meissa Vaccines and Novavax. Emerging players are CaroGen Corporation and Vyriad.

Does Codagenix have an API?

No public API is recorded for Codagenix.

What industry is Codagenix in?

Codagenix's product category is Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarVaxThera and Codagenix Partner to Advance a Next Generation Yellow Fever VaccineVaxThera will exclusively license Codagenix's yellow fever vaccine candidate Syn17D-YF, a fully synthetic DNA virus, to advance it through manufacturing, preclinical, and clinical development. The vaccine is designed for modern cell-culture production, addressing egg-based manufacturing limitations and potential supply shortages.Genetic Literacy ProjectWhen will needle-free COVID vaccines arrive in the US?The US federal government is funding two companies, Codagenix and CastleVax, with nearly $20 million to test mucosal COVID vaccines. Five such vaccines are currently in use in China, India, Iran, Indonesia, Morocco, and Russia, with more in trials.PR NewswireCodagenix Announces Presentation of Updated Preclinical CodaLytic™ Data at Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingCodagenix Inc. announced the presentation of preclinical data for CodaLytic, a codon-modified virus being developed for breast cancer immunovirotherapy, at the Society for Immunotherapy of Cancer 38th Annual Meeting in November 2023. The data demonstrated that CodaLytic treatment induced tumor immune infiltration and anti-tumor efficacy in multiple preclinical models. The company stated these results underscore the potential of CodaLytic as a component of novel therapeutic regimens for breast cancer patients.BioSpaceCodagenix Receives Additional Award from US Department of Defense to Advance Development of Dengue VaccineCodagenix received a $5.88 million award from the U.S. Department of Defense to advance its CodaVax-DENV dengue vaccine into clinical trials. The funding will support good manufacturing practices and a first-in-human Phase 1 safety and immunogenicity study for the tetravalent live attenuated vaccine. This award complements a previous $4.4 million grant from 2022 under the Joint Warfighter Medical Research Program.PR NewswireCodagenix Receives Additional Award from US Department of Defense to Advance Development of Dengue VaccineCodagenix Inc. has received a $5.88 million award from the US Department of Defense to advance its CodaVax-DENV dengue vaccine into clinical trials. The funding supports good manufacturing practices and a first-in-human Phase 1 safety and immunogenicity study for the tetravalent live attenuated vaccine.HHS.govProject NextGen Selects Initial Vaccine Candidates and Awards Over $500 Million to Advance Development of Vaccines and TherapeuticsHHS announced initial next-generation vaccine candidates and over $500 million in awards for Project NextGen, accelerating planning for Phase 2b clinical trials. The funding includes $8.5 million to CastleVax, $10 million to Codagenix, and $10 million to Gritstone Bio, with additional support for testing and delivery technologies.PR NewswireCodagenix Initiates Dosing in Phase 1 Study of Intranasal, Live-Attenuated RSV Vaccine, CodaVax™- RSV, in a Pediatric PopulationCodagenix Inc. has initiated dosing in a Phase 1 pediatric study evaluating CodaVax™-RSV, a live-attenuated intranasal vaccine candidate for RSV prevention in children aged 6 months to 5 years, under FDA IND with Fast Track designation. The trial uses an age de-escalation, dose escalation design to assess safety and immunogenicity. According to CDC data cited, the 6-month to 1-year-old population experiences RSV-associated hospitalization rates of 99.1 per 100,000, compared to 6.5 per 100,000 in those over 65, representing a 15-fold higher burden in the pediatric segment that existing maternal immunization and antibody strategies do not fully address.YahooWhat next-gen Covid-19 vaccines might look likeNext-generation Covid-19 vaccines are under development, including live-attenuated, nasal, broad-spectrum, and self-boosting types. Codagenix's live-attenuated nasal vaccine is in phase 3 trials, while others like Vaxart's pill and MIT's time-release boosters are in early testing. Experts expect these vaccines to reduce transmission and provide broader protection.BioSpaceCodagenix Announces Appointment of Kimber Poffenberger, Ph.D., as Chief Strategy OfficerCodagenix appointed Kimber Poffenberger, Ph.D., as Chief Strategy Officer. She brings over 20 years of regulatory and product leadership, including roles at GSK Vaccines and Merck. The appointment aims to support Codagenix's pipeline of live-attenuated vaccines and cancer virotherapeutics.SecSEC FORM DCodagenix Inc. filed a Form D with the SEC to announce an exempt offering of securities under Rule 506(b). The filing indicates that the company has sold $25,005,232 USD in equity securities to five investors as of February 10, 2023. This regulatory submission serves as a formal notice of the private placement for biotechnology development purposes.